Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor.
There is now evidence that schizophrenia may be accompanied by an activation of the monocytic and T-helper-2 (Th-2) arms of cell-mediated immunity (CMI) and by various alterations in the Th-1 arm of CMI. There is also evidence that repeated administration of typical and atypical antipsychotics may result in negative immunomodulatory effects. This study was carried out to examine (1) the serum concentrations of interleukin-8 (IL-8), IL-10, the soluble CD8 (sCD8) and the leukemia inhibitory factor receptor (LIF-R) in nonresponders to treatment with typical neuroleptics as compared with normal volunteers and responders to treatment; and (2) the effects of atypical antipsychotics on the above immune variables. The latter were determined in 17 nonresponders to treatment with neuroleptics and in seven normal volunteers and 14 schizophrenic patients who had a good response to treatment with antipsychotic agents. The nonresponders had repeated measurements of the immune variables before, and 2 and 4 months after treatment with clozapine or risperidone. Serum IL-8 and IL-10 were significantly higher in schizophrenic patients than in normal controls. The serum concentrations of the sCD8 were significantly increased 2 months, but not 4 months, after starting treatment with atypical antipsychotics. Serum LIF-R concentrations were significantly increased 2 and 4 months after starting treatment with atypical antipsychotics. It is concluded that: (1) schizophrenia is characterized by an activation of both pro-inflammatory and anti-inflammatory aspects of cell-mediated immunity; (2) prolonged treatment with atypical antipsychotics may increase the anti-inflammatory capacity of the serum in schizophrenic patients by increasing serum LIF-R concentrations; and (3) short-term treatment with clozapine may induce signs of immune activation which disappear upon prolonged treatment.
Maes
Michael
M
IRCCS, Istituto, Fatebenefratelli, Brescia, Italy.crc-mh@online.be
Bocchio Chiavetto
Luisella
L
Bignotti
Stefano
S
Battisa Tura
Giani-Jean
GJ
Pioli
Rosaria
R
Boin
Francesco
F
Kenis
Gunter
G
Bosmans
Eugene
E
de Jongh
Raf
R
Altamura
Carlo A
CA
D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000276:immunology* / Q000494:pharmacology; D016022:Case-Control Studies; D003024:Clozapine / Q000276:immunology* / Q000494:pharmacology; D004351:Drug Resistance / Q000276:immunology*; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood*; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008297:Male; D008875:Middle Aged; D018121:Receptors, Cytokine / Q000097:blood / Q000187:drug effects*; D053606:Receptors, OSM-LIF; D012044:Regression Analysis; D012559:Schizophrenia / Q000188:drug therapy* / Q000276:immunology*
D014150:Antipsychotic Agents; D016209:Interleukin-8; C507840:LIFR protein, human; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D018121:Receptors, Cytokine; D053606:Receptors, OSM-LIF; D016753:Interleukin-10; D003024:Clozapine